FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction

1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL				
OMB Number:	3235-0287			
Expires:	December 31, 2014			
Estimated average burden				
hours per response	0.5			

1. Name and Address of Reporting Person* PERCEPTIVE ADVISORS LLC			2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC [ACRX]				
(Last) 499 PARK AV	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/23/2013	(Check all applicable) Director X 10% Owner Officer (give title below) (specify below)			
(Street) NEW YORK (City)	NY (State)	10022 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Instr. 8)		Acquired Disposed	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or		Acquired (A) or Disposed of (D) Instr. 3, 4 and 5) (A) Or (A) Or (A) Or (Instr. 3 and		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/23/2013		Р		850,000	Α	\$ 11.65	5,858,400	I	See Footnotes	

			(3-, ,	,	, - -		-,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)			
				Code V	(A) (D)	Da Exerc	ate isable	Expiration Date	
		dress of Repo	_	*					
(Last) 499 PA	RK AVEN	(First) NUE, 25TH FL		(Middle)					
(Street)		NY		10022					
(City)		(State)	ı	(Zip)					
	e and Add	dress of Repo	orting Person	*					
(Last) C/O PE FLOOF		(First) /E ADVISOR		(Middle) ARK AVE	NUE, 25 ⁻	ΤΗ			
(Street)		NY		10022					
(City)		(State)		(Zip)					
		dress of Repo	-						
(Last) C/O PE FLOOF		(First) /E ADVISOR		(Middle) ARK AVE	NUE, 25 ⁻	ГН			
(Street)		NY		10022					
(City)	(City) (State)				(Zip)				

Explanation of Responses:

1. This Form 4 is being filed by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"), Perceptive Advisors LLC (the "Advisor") and Joseph Edelman. The Advisor serves as investment manager to the Master Fund and to a managed account (the "Managed Account") for BioEdelman LLC, an entity directly owned by Mr. Edelman. Mr. Edelman is the managing member of the Advisor.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

7. Title and

Underlying

(Instr. 3 and

Amount or Number

of Shares

Amount of

Securities

8. Price of

Derivative

(Instr. 5)

9. Number of

Derivative

Securities

Owned Following

Reported

Transaction(s) (Instr. 4)

Beneficially

10.

Ownership

Derivative

Security: Direct (D)

or Indirect

(Instr. 4)

Form of

11. Nature

of Indirect

Beneficial

Ownership

(Instr. 4)

- 2. This transaction reflects the purchase of securities by the Advisor on behalf of the Master Fund.
- 3. This amount reflects the total amount of securities held by the Master Fund immediately following the transaction requiring the filing of this statement. In accordance with Instruction 5(b)(iv) of Form 4, the entire amount of the Issuer's securities held by the Master Fund is reported herein. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Perceptive Advisors LLC

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Information Regarding Joint Filers

Designated Filer of Form 4: Perceptive Advisors LLC

Date of Earliest Transaction Required to be Reported: July 23, 2013

Issuer Name and Ticker Symbol: AcelRx Pharmaceuticals, Inc. [ACRX]

Names: Perceptive Life Sciences Master Fund Ltd. and Joseph Edelman

Address: Perceptive Advisors LLC

499 Park Avenue, 25th Floor

New York, NY 10022

Signatures:

The undersigned, Perceptive Life Sciences Master Fund Ltd. and Joseph Edelman, are jointly filing the attached Statement of Changes in Beneficial Ownership of Securities on Form 4 with Perceptive Advisors LLC with respect to the beneficial ownership of securities of AcelRX Pharmaceuticals, Inc.

Perceptive Life Sciences Master Fund Ltd.

By: Perceptive Advisors LLC, its investment manager

By: /s/ Joseph Edelman

Joseph Edelman, managing member

JOSEPH EDELMAN

/s/ Joseph Edelman

By: Joseph Edelman